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Abstract
Background: The purpose of this study was to evaluate the imaging properties of hepatic metastases in 68Ga-PSMA
positron emission tomography (PET) in patients with prostate cancer (PC).
Methods: 68Ga-PSMA-PET/CT scans of PC patients available in our database were evaluated retrospectively for liver
metastases. Metastases were identified using 68Ga-PSMA-PET, CT, MRI and follow-up scans. Different parameters
including, maximum standardized uptake values (SUVmax) of the healthy liver and liver metastases were assessed by
two- and three-dimensional regions of interest (2D/3D ROI).
Results: One hundred three liver metastases in 18 of 739 PC patients were identified. In total, 80 PSMA-positive (77.7%)
and 23 PSMA-negative (22.3%) metastases were identified. The mean SUVmax of PSMA-positive liver metastases
was significantly higher than that of the normal liver tissue in both 2D and 3D ROI (p≤ 0.05). The mean SUVmax of
PSMA-positive metastases was 9.84 ± 4.94 in 2D ROI and 10.27 ± 5.28 in 3D ROI; the mean SUVmax of PSMA-negative
metastases was 3.25 ± 1.81 in 2D ROI and 3.40 ± 1.78 in 3D ROI, and significantly lower than that of the normal liver
tissue (p≤ 0.05). A significant (p≤ 0.05) correlation between SUVmax in PSMA-positive liver metastases and both size
(ρSpearman = 0.57) of metastases and PSA serum level (ρSpearman = 0.60) was found.
Conclusions: In 68Ga-PSMA-PET, the majority of liver metastases highly overexpress PSMA and is therefore directly
detectable. For the analysis of PET images, it has to be taken into account that also a significant portion of metastases
can only be detected indirectly, as these metastases are PSMA-negative.
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Background
Worldwide, prostate cancer (PC) is considered the second
most frequently diagnosed cancer in men and the fifth
leading cause of cancer death [1]. Recently, radiolabeled
prostate-specific membrane antigen (PSMA) ligands such
as 68Ga-PSMA-HBED-CC have been introduced as a
promising radiotracer for the PET imaging of PC [2].
PSMA is a transmembrane protein that is significantly
overexpressed in most prostate cancer cells [3]. Different
studies demonstrated that 68Ga-PSMA–PET enables
imaging with a higher specificity and sensitivity regarding
the detection of metastases, compared to current standard
imaging (CT, MRI and bone scintigraphy) and other PET
tracers such as 18F-Choline [4–7]. It also improves detec-
tion of metastatic lesions at low serum PSA levels in bio-
chemically recurrent prostate cancer [8].
The liver is considered to be the third most common
site for systemic metastases in PC (25%), after bone
(90%) and lung (46%), according to autopsy studies [9].
The prevalence of clinical liver metastases in retrospect-
ive studies was 4.3 and 8.0% [10, 11]. Liver metastases
typically occur in systemic, late stage, hormone refrac-
tory disease [10]. However, there are reports of pa-
tients with liver metastases as the first site of
metastatic disease and the liver representing the only
metastatic site [10, 12, 13]. Especially in this patient
collective, early and reliable detection of liver
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metastases is of high clinical importance for accurate
staging and therapy planning.
There is evidence that in PC, liver metastases are fre-
quently associated with neuroendocrine characteristics;
in a prospective study of 28 patients with liver metasta-
ses, Pouessel et al. measured increased levels of the
neuroendocrine serum markers chromogranin A and
neurone-specific enolase in 84 and 44% of the patients,
and out of six patients with a pathological analysis, two
had neuroendocrine metastases [10]. Neuroendocrine
transdifferentiation might lead to loss of PSMA-
expression and therefore impede the visualization of
liver metastases in 68Ga-PSMA-PET [14]. Furthermore,
the relatively high background activity of the liver
might also affect the visibility of liver metastases in
68Ga-PSMA-PET [14]. Imaging of hepatic PC metasta-
ses in 68Ga-PSMA-PET has been reported in case re-
ports, but not been systematically researched in a larger
cohort of patients [12, 15–18].
Therefore, the aim of this study was to investigate the




For this retrospective study, we obtained approval from
our institutional ethics review board. We extracted 739
consecutive patients with confirmed prostate cancer
from our local database who underwent at least one
68Ga-PSMA-PET/CT between September 2013 and
April 2017. Out of these, we identified eighteen patients
with liver metastases, according to the criteria described
below. Prostate cancer was histologically proven in all
patients. Only patients with no other known type of
cancer but PC were included. All available additional in-
formation from clinical records were obtained. Patients’
characteristics are summarized in Table 1. Gleason score
(GS) was available in eleven, therapy information only in
thirteen and PSA level only in twelve patients.
Positron emission tomography tracer
68Ga was eluted from a conventional 68Ge/68Ga radio-
nuclide generator (Eckert & Ziegler Radiopharma GmbH,
Berlin, Germany) and compounded with PSMA-HBED-
CC (ABX GmbH, Radeberg, Germany) according to the
method described previously [19, 20].
Imaging protocol
PET/CT imaging was performed 75.8 ± 18.2min after
intravenous injection of 120.5 ± 25.7MBq of 68Ga-PSMA.
PET scans were acquired using a Gemini Astonish TF 16
PET/CT scanner (Phillips Medical Systems) in 3D acquisi-
tion mode [21]. Axial, sagittal and coronal slices were
reconstructed (144 voxels with 4mm3, isotropic). Before
PET scan, a low-dose CT was performed for anatomical
mapping and attenuation correction (30 mAs, 120 kVp).
Each bed position was acquired for 1.5 min with a 50%
overlap. In case contrast-enhanced CT (CE-CT) was
performed, 80–120ml of contrast agent (Ultravist® 370,
Bayer Schering Pharma, Berlin, Germany) was injected
intravenously with a delay of 70 s for the venous phase.
Imaging analysis
Two experienced observers analyzed the PET/CT scans
using Visage 7.1 (Visage Imaging GmbH, Berlin,
Germany). For the diagnosis of metastases, all available
imaging studies including all imaging modalities (CT,
MRI, 68Ga-PET) of the patients were taken into consid-
eration. At least two of the following four criteria had to
be fulfilled for the diagnosis of liver metastasis: (I) CT
imaging with low-to-isoattenuating masses [22]; (II) MRI
with typical presentation of liver metastases according to
guidelines [23]; (III) high focal uptake of 68Ga-PSMA in
PET distinctively above normal heterogeneity; (IV) new
appearance or significant change of size of lesions
according to the RECIST 1.1 criteria compared to previ-
ous studies within the same modality with a minimum
follow-up interval of six months [24]. Patients with signs
of a malignancy other than PC were excluded. Out of 23
patients with suspected liver metastases, five patients
dropped out because they did not fulfill these criteria.
Overall 18 patients with hepatic metastases were identi-
fied out of 739 patients. Among these, criteria I was ful-
filled by all patients, criteria II by four patients, criteria
III by 16 patients and criteria IV by 12 patients.
Maximum ten metastases per patient were analyzed. In
case a patient was imaged more than once, only the
most recent 68Ga-PSMA-PET scan was included in this
study. As a result, 103 liver metastases were analyzed as
Table 1 Characteristics of the study collective of PC patients
with liver metastases
Characteristic Mean ± SD Median (Range) n (%)
Age (years) 70.1 ± 8.5 71.0 (54.5–81.4)
PSA (ng/ml) 556.3 ± 1398.4 124.6 (0.01–4962.0)







RP Radical prostatectomy, RT Radiotherapy, ADT Androgen deprivation
therapy, CTX Chemotherapy
Summary of the patients’ characteristics, including age, PSA, GS, indication for
imaging and previous therapy, at the time imaging was performed. GS Gleason
score, PSA prostate-specific antigen
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part of this study. The sizes of metastases were mea-
sured based on the CT scan. Regarding the evaluation of
the radiodensity, two groups were formed. One group in
which only unenhanced CTs were available (five pa-
tients) and another group in which contrast-enhanced
CTs were available (13 patients).
To normalize standardized uptake values (SUV) for
body weight, they were calculated by the software using
with the equation SUV =Ctis/Qinj/BW, where Ctis is the
lesion activity concentration in MBq per milliliter, Qinj is
the activity injected in MBq, and BW is the bodyweight
in kilograms. For PET data quantification, a two-
dimensional region of interest (2D ROI), as well as a
three-dimensional region of interest (3D ROI), were
defined. 68Ga-PSMA-HBED-CC uptake was quantified
using maximum standardized uptake values (SUVmax).
All values were recorded in the transaxial, attenuation-
corrected PET-slice representing the greatest extent of
the respective lesion. Regions of interest were defined
manually in freehand mode avoiding the periphery of
lesions to minimize partial volume effects. SUVmax of
the healthy liver was measured in a region with minimal
irregularities. An SUVmax-lesion-to-background ratio
(LBR) was calculated for all metastases in 3D ROI, using
the formula LBR ¼ SUVmax of metastasisSUVmax of liver . Any tracer uptake
20% or more above liver uptake was considered PSMA-
positive, any tracer uptake below that was considered
PSMA-negative. The readers were blinded to the results
of other diagnostic procedures and the clinical history of
the patients.
Statistical analysis
The descriptive statistics are reported as mean, median
and/or range when applicable. Nonparametric statistical
tests were used as the data contained several outliers. The
Mann-Whitney U test was used for the comparison of
SUVmax values and mean radiodensity values (HUmean)
between the healthy liver and liver metastases. SUVmax
values in 2D and 3D ROI were compared using the
Wilcoxon signed-rank test. To determine the relationship
between SUVmax and size of lesions, patients’ age and PSA
serum level, a Spearman’s rank correlation was used. A bi-
nomial test was run to evaluate the distribution of liver
metastases among the hepatic lobes. The significance level
was set to α < 0.05. Statistical analyses were conducted
with SPSS 23 for Mac (IBM Corp, Armonk, NY).
Results
Characteristics of the study patients
In total, 103 liver metastases were detected in 18 of 739
(2.44%) patients. Patients’ characteristics are summarized
in Table 1. Mean patients’ age was 70.1 ± 8.5 years.
Median GS was 9 (range 6–10). Mean PSA level was
556.3 ± 1398.4 ng/ml.
Lesion-based analysis of liver metastases
All detailed results are depicted in Table 2. The mean
size of metastases was 3.3 ± 4.7 cm2 (range 0.2–29.5cm2).
The mean SUVmax of all liver metastases was 8.4 ± 5.2 in
2D and 8.7 ± 5.5 in 3D ROI, compared to a mean SUV-
max of the normal liver of 4.8 ± 2.3 in 2D and 5.3 ± 2.3 in
3D ROI. The mean SUVmax of all liver metastases was
significantly higher than the SUVmax of normal liver in
both 2D (p ≤ 0.05) and 3D ROI (p ≤ 0.05). In total, 80
PSMA positive (77.7%) and 23 PSMA negative (22.3%)
metastases were identified. Examples of PSMA-positive
and PSMA-negative metastases are illustrated in Figs. 1
and 2. The mean SUVmax of PSMA-positive metastases
was 9.8 ± 4.9 in 2D (see Fig. 3) and 10.3 ± 5.3 in 3D ROI.
The mean SUVmax of PSMA-negative metastases was
3.3 ± 1.8 in 2D and 3.4 ± 1.8 in 3D ROI. This was signifi-
cantly lower than the mean SUVmax of the normal liver,
in both 2D (p ≤ 0.05) and 3D ROI (p ≤ 0.001). The mean
SUVmax obtained by 3D ROI was significantly higher
than that obtained by 2D ROI in normal liver (p ≤ 0.05)
as well as in PSMA-positive liver metastases (p ≤ 0.001).
There was no difference in SUVmax of PSMA-negative
metastases between 2D and 3D ROI (p > 0.05). The
mean SUVmax-lesion-to-background ratio in PSMA-
positive liver metastases was 2.7 ± 1.5, which was signifi-
cantly higher than that of PSMA-negative metastases
(0.5 ± 0.3, p ≤ 0.001, see Fig. 4).
HUmean of liver metastases compared to the normal liver
The mean CT attenuation value of liver metastases was
significantly lower than that of the normal liver, in CE-
CT (p ≤ 0.001) and unenhanced CT (p ≤ 0.05). In liver
metastases, HUmean was 61.0 ± 25.1 in CE-CT and
31.1 ± 13.9 in unenhanced CT, whereas the HUmean of
the normal liver was 102.2 ± 17.1 in CE-CT and 53.8 ±
8.9 in unenhanced CT. In PSMA-negative metastases,
HUmean was 30.4 ± 19.7 in CE-CT and 19.1 ± 5.3 in
unenhanced CT. In PSMA-positive metastases, HUmean
was 67.0 ± 21.5 in CE-CT and 40.4 ± 11.1 in unenhanced
CT. HUmean of PSMA-negative metastases was found to
be significantly lower than that of PSMA-positive metas-
tases, in both contrast-enhanced and unenhanced CT
(both p ≤ 0.001).
Correlation between size and SUVmax of liver metastases
We calculated a moderate significant positive relation-
ship between size and SUVmax of PSMA-positive
metastases (Fig. 5a, ρSpearman = 0.568, 95% CI [0.397;
0.701], p ≤ 0.001).
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Table 2 Comparison of size, 68Ga-PSMA-HBED-CC uptake (SUVmax) and radiodensity (HUmean) between normal liver and liver metastases
(all, PSMA-positive and PSMA-negative)
Normal liver All liver metastases PSMA positive metastases PSMA negative metastases p-value
Number 18 103 80 23
Size in cm2 3.27 ± 4.73 (0.2–29.5) 2.69 ± 4.95 (0.2–29.5) 5.29 ± 3.23 (2.1–14.3)
SUVmax 2D ROI 4.84 ± 2.29 (2.9–10.7) 8.37 ± 5.22 (1.0–26.3) ≤0.05
9.84 ± 4.94 (3.6–26.3) ≤0.001
3.25 ± 1.81 (1.0–7.5) ≤0.05
SUVmax 3D ROI 5.32 ± 2.28 (3.0–11.9) 8.73 ± 5.53 (1.4–26.3) ≤0.05
10.27 ± 5.28 (3.6–26.3) ≤0.001
3.40 ± 1.78 (1.4–7.8) ≤0.001
HUmean, CE-CT 102.18 ± 17.09 (56.5–124.0) 61.04 ± 25.10 (16.4–124.2) ≤0.001
67.0 ± 21.49 (16.5–124.2) ≤0.001
30.35 ± 19.71 (16.4–65.0) ≤0.001
HUmean, unenhanced CT 53.76 ± 8.89 (38.2–60.6) 31.10 ± 13.94 (8.5–50.7) ≤0.05
40.36 ± 11.05 (8.5–50.7) ≤0.05
19.07 ± 5.27 (13.1–26.5) ≤0.05
All data are given as mean ± standard deviation and range in parentheses. SUVmax Maximum standardized uptake value, ROI Region of interest, HUmean Mean Hounsfield
units, CE-CT Contrast-enhanced CT
The mean SUVmax of all liver metastases was significantly higher than the SUVmax of the normal liver, both in 2D (p ≤ 0.05) and 3D ROI (p ≤ 0.05). The mean SUVmax
of PSMA-negative liver metastases was significantly lower than the SUVmax of the normal liver, in 2D (p ≤ 0.05) and 3D ROI (p ≤ 0.001). The mean CT attenuation
value HUmean of PSMA-positive metastases was significantly lower than that of normal liver, in contrast-enhanced (p ≤ 0.001) as well as in unenhanced CT
(p ≤ 0.05). SUVmax Maximum standardized uptake value, ROI Region of interest, HUmean Mean Hounsfield units
Fig. 1 Example of 68Ga-PSMA-positive liver metastases in a PC patient with a recurrent acinar adenocarcinoma. a, b: 68Ga-PSMA-PET/CT of a 68-
year-old patient with a recurrent acinar adenocarcinoma of the prostate. At initial diagnosis in 2007, the GS was 5 + 5. The patient received primary
radiotherapy and undergone chemotherapy as well as androgen-deprivation therapy. The serum PSA was 606 ng/ml at the time of examination.
Besides disseminated osseous metastases (such as in a vertebral body, blue arrows) and a singular lymph node metastasis in the axilla, the PET/CT (a)
revealed small-nodular, PSMA-positive liver metastases in all segments, with SUVmax-values up to 26.3 (exemplary in segments VII/VIII, green arrows). In
contrast-enhanced CT (b), liver metastases appear ill-defined and hypodense compared to the liver, typical for hypovascular metastases. GS Gleason
score, PSA prostate-specific antigen, SUVmax Maximum standardized uptake value
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Fig. 2 Example of 68Ga-PSMA-negative liver metastases in a PC patient with a recurrent adenocarcinoma. a, b: 68Ga-PSMA-PET/CT of a 54-year-old
patient with a recurrent adenocarcinoma of the prostate and disseminated lymph node, bone, and hepatic metastases. After the initial diagnosis in
2011, the patient had received a radical prostatectomy and undergone chemotherapy as well as androgen-deprivation therapy. The serum PSA was
4962.0 ng/ml at the time of examination; the initial GS was 4 + 5. The PET/CT (a) illustrates disseminated, PSMA-negative liver metastases, with SUVmax-
values up to 4.2 (liver background 9.5). Green arrows point to examples of liver metastases in segments IVa and V. In CE-CT (b), liver metastases appear
hypodense compared to the liver. GS Gleason score, PSA prostate-specific antigen, SUVmax Maximum standardized uptake value
Fig. 3 SUVmax of the normal liver, PSMA-positive and PSMA-negative liver metastases in 2D ROI. The mean SUVmax of PSMA-positive liver metastases
was 9.8 ± 4.9 and significantly higher than the mean SUVmax of the normal liver (4.8 ± 2.3, p≤ 0.001). In contrast, the mean SUVmax of PSMA-negative
liver metastases was 3.3 ± 1.8 and significantly lower than that of the normal liver (p≤ 0.05). SUVmax Maximum standardized uptake value
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Patient-based analysis and correlation between PSA,
patients’ age, and SUVmax
Of 18 patients with liver metastases, eight patients (44,
4%) had ten or more metastases, three patients (16.7%)
had two to ten metastases, and seven patients (38.9%)
had a single metastasis. Regarding the tracer uptake, 15
patients (83.3%) had PSMA-positive hepatic metastases
only, two patients (11.1%) had PSMA-negative metasta-
ses only, and one patient (5.6%) had mixed metastases.
The distribution of liver metastases by liver segments is
illustrated in Fig. 6. A higher number of patients had
liver metastases in the right (100%) than in the in the
left hepatic lobe (61.1%, p > 0.05). A weak, significant
negative relationship between patients’ age and SUVmax
of PSMA-positive metastases was calculated (Fig. 5b,
ρSpearman = − 0.221, 95% CI [− 0.420; − 0.002], p ≤ 0.05).
Also, there was a moderate, significant positive correl-
ation between the PSA serum level at the time of
Fig. 4 Mean SUVmax-lesion-to-background ratio of PSMA-positive and PSMA-negative liver metastases. The mean SUVmax-lesion-to-background
ratio in PSMA-positive liver metastases was 2.7 ± 1.5 and significantly higher than that of PSMA-negative metastases (0.5 ± 0.3, p ≤ 0.001). SUVmax
Maximum standardized uptake value
Fig. 5 Correlations between metastases’ size, patients’ age, serum PSA and SUVmax of metastases. a-c: Correlations according to a Spearman’s
correlation, including 95% confidence intervals. A moderate significant association between the SUVmax in liver metastasis and its size (a) was
calculated (p ≤ 0.001, ρSpearman = 0.568, 95% CI [0.397, 0.701]). Patient’s age and SUVmax of liver metastases (b) weakly correlate (p ≤ 0.05,
ρSpearman = − 0.221, 95% CI [− 0.420; − 0.002]). Serum PSA and SUVmax of liver metastases (c) moderately correlate (p≤ 0.001, ρSpearman = 0.601, 95%
CI [0.419; 0.736]). R2 Coefficient of determination, r Spearman’s rho, SUVmax Maximum standardized uptake value, PSA Prostate-specific antigen
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examination and SUVmax of PSMA-positive metastases
(Fig. 5c, ρSpearman = 0.601, 95% CI [0.419; 0.736], p ≤ 0.001).
Discussion
This study evaluated the imaging characteristics of liver
metastases in 68Ga-PSMA-PET. It was demonstrated
that the majority of liver metastases highly overexpress
PSMA and is therefore directly detectable by 68Ga-
PSMA-PET. For the analysis of PET images, it has to be
taken into account that also a significant portion of
metastases can only be detected indirectly, as these
metastases are PSMA-negative.
68Ga-PSMA-PET/CT has demonstrated potential to
improve the initial staging, lymph node staging, and
detection of recurrence of PC, even at low PSA levels.
Several studies have indicated that 68Ga-PSMA-PET is
more accurate compared to other tracers as such as 18F-
choline [25]. So far, the imaging properties of liver
metastases in 68Ga-PSMA-PET have not been systemat-
ically researched.
In our cohort, liver metastases were present in 2.4% of
patients who underwent 68Ga-PSMA-PET. This was
lower compared to the prevalence reported by other
studies, likely as a result of the different study designs
and the limited sensitivity of PET for the detection of
small (< 1 cm) metastases [10, 11]. In our study popula-
tion, the majority of patients demonstrated PSMA-
positive hepatic metastases, while only a small number
of patients demonstrated PSMA-negative or mixed
metastases. An explanation for the difference of 68Ga-
PSMA-HBED-CC uptake in liver metastases could be
the diversity of phenotypes in metastases, predominantly
the neuroendocrine trans-differentiation. In PC, liver
metastases are frequently associated with neuroendo-
crine characteristics as well as with advanced state in
systemic disease [10]. It is thought that the degree of
neuroendocrine trans-differentiation increases with dis-
ease progression and in response to ADT [26]. A
pronounced elevation of neuroendocrine serum markers
such as neuron-specific enolase and chromogranin A
has been demonstrated in patients with long duration of
ADT [27]. Autopsy studies have confirmed the pheno-
typic heterogeneity of end-stage metastatic prostate
cancer [28, 29]. A large part of neuroendocrine prostate
cancer cells does not express generic PC biomarkers
including P501S, PSMA, and PSA [30]. This is consist-
ent with the histopathologic finding in one of our study
patients with PSMA-negative liver metastases, in whom
liver and prostate biopsy were performed. Histopath-
ology of the metastasis revealed an infiltration of the
liver with neuroendocrine carcinoma cells, which were
positive for the neuroendocrine biomarker CD56, but
negative for PSA, PSMA and androgen receptor. In the
same patient, histopathology of the prostate tissue
Fig. 6 Patient-based analysis of the localization of liver metastases, according to liver segments. Percentages indicate the proportion of study patients
in whom liver metastases were localized within the respective liver segment. Liver segment VI was the most common localization for liver metastases
(80%), whereas liver segment I was the least common site (44%)
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exposed an acinar adenocarcinoma with 5% of the cells
presenting neuroendocrine markers, which can be inter-
preted as a partial trans-differentiation. The findings of
this study are also consistent with a case report by Usmani
et al. of a PC patient with an unsuspicious 68Ga-PSMA-
PET, whereas a 68Ga-DOTANOC-PET performed ten
days later revealed multiple somatostatin-avid hepatic and
lymph node metastases, and lymph node cytology con-
firmed neuroendocrine differentiation [31]. Overall, neu-
roendocrine trans-differentiation could explain the loss of
PSMA-expression of liver metastases in progressive dis-
ease. Vice versa, the detection of PSMA-underexpression
in liver metastases could represent trans-differentiation;
clinicians need to be familiar with this concept as it may
result in treatment adaptation.
Interestingly, the radiodensity of PSMA-negative liver
metastases was significantly lower compared to the
PSMA-positive metastases, in both unenhanced and
contrast-enhanced CTs. This finding could further
support the differentiation of liver metastases in PC but
needs to be verified in a larger cohort.
Additionally, a significant positive correlation between
the serum PSA level at the time of examination and
SUVmax of PSMA-positive liver metastases was ob-
served. This could be explained by the fact that both pa-
rameters tend to increase within the progression of the
disease. The finding is consistent with the studies of
Koerber et al. and Sachkepides et al., who reported that
patients with higher PSA values demonstrated a signifi-
cant higher tracer uptake in intraprostatic tumor lesions
on PSMA-PET/CTs [32, 33]. Between the size and SUV-
max of PSMA-positive liver metastases, a weak but
significant association was found. This might be the
result of a proliferative advantage of highly PSMA-
expressing cells, as it has been demonstrated in-vitro
[34]. We further observed a weak but significant, nega-
tive association between age and SUVmax of PSMA-
positive liver metastases. A hypothesis explaining this
finding could be that patients who develop liver metasta-
ses at a younger age have a more aggressive subtype of
PC with higher PSMA-expression. This, however, needs
to be investigated in a larger cohort.
A limitation of this retrospective study is that diagno-
ses of liver metastases were not confirmed histopatho-
logically since no biopsies of most of the metastases
were performed. A possible limitation to the lesion-
based analysis regarding the calculation of mean SUVmax
values could be due to an overestimation of the patients
subgroup with multiple metastases compared to the sub-
group with few metastases.
Conclusions
The majority of liver metastases highly overexpress
PSMA in 68Ga-PSMA-PET and is therefore directly
detectable. For the analysis of PET images, it has to be
taken into account that also a significant portion of
metastases can only be detected indirectly, as these
metastases are PSMA-negative. Future studies are
warranted to test these findings in a larger collective of
patients and to correlate changes on histopathology with
the PSMA expression.
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